Showing results (1361-1370 of 1,380) with videos related to

Sort By:
Pageof 138
The Lancet. Infectious Diseases|January 28, 2023
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialKirsten E Lyke, Andrea A Berry, Kaitlin Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
Physical Review Letters|October 20, 2018
First Accurate Normalization of the β-delayed α Decay of ^{16}N and Implications for the ^{12}C(α,γ)^{16}O Astrophysical Reaction RateO S Kirsebom, O Tengblad, R Lica, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2017
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infectionKirsten E Lyke, Andrew S Ishizuka, Andrea A Berry, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Neratinib in Early Breast CancerJohn W Park, Minetta C Liu, Douglas Yee, et al.
Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast CancerHope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, et al.
Cancer Cell|November 18, 2022
Evaluation of cell-free DNA approaches for multi-cancer early detectionArash Jamshidi, Minetta C Liu, Eric A Klein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 TrialA Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Pageof 138